Governments must create meaningful incentives for biopharmaceutical companies to develop antimicrobial products. Antimicrobial resistance (AMR) is an inevitable evolutionary process — resistance will occur, and it will spread globally. We are in a race to maintain a portfolio of effective antibiotics, and we are falling behind.
Article in Nature Outlook: Antimicrobial Resistance